{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:38:07Z","timestamp":1767339487740},"reference-count":20,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p>Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus\u2013infected persons in leishmaniasis-endemic areas. The standard treatment may not be effective and relapses are common. We report the case of a human immunodeficiency virus-1\u2013infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy.<\/jats:p>","DOI":"10.4269\/ajtmh.2010.09-0594","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T16:25:01Z","timestamp":1278001501000},"page":"10-12","source":"Crossref","is-referenced-by-count":12,"title":["Visceral Leishmaniasis Treated with Antimonials\/Paromomycin followed by Itraconazole\/Miltefosine after Standard Therapy Failures in a Human Immunodeficiency Virus\u2013Infected Patient"],"prefix":"10.4269","volume":"83","author":[{"given":"Patricia","family":"Barrag\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"L\u00f3pez-Velez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"R1","series-title":"J Clin Microbiol","first-page":"762","article-title":"Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy","volume":"40","author":"de La Rosa","year":"2002"},{"key":"R2","series-title":"Clin Microbiol Rev","first-page":"334","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years","volume":"21","author":"Alvar","year":"2008"},{"key":"R3","series-title":"Trop Med Int Health","first-page":"849","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001"},{"key":"R4","series-title":"Expert Opin Pharmacother","first-page":"2821","article-title":"Treatment of visceral leishmaniasis","volume":"6","author":"Sundar","year":"2005"},{"key":"R5","series-title":"Scand J Infect Dis","first-page":"78","article-title":"Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients","volume":"40","author":"Troya","year":"2008"},{"key":"R6","series-title":"Int J Antimicrob Agents","first-page":"590","article-title":"Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration","volume":"31","author":"Manfredi","year":"2008"},{"key":"R7","series-title":"Biomedica (Bogota)","first-page":"207","article-title":"Oral miltefosine to treat leishmaniasis","volume":"26","author":"Soto","year":"2006"},{"key":"R8","series-title":"Trans R Soc Trop Med Hyg","first-page":"653","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009"},{"key":"R9","series-title":"N Engl J Med","first-page":"2571","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007"},{"key":"R10","series-title":"BMJ","first-page":"1200","article-title":"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India","volume":"316","author":"Jha","year":"1998"},{"key":"R11","series-title":"Am J Med","first-page":"449","article-title":"Maintenance itraconazole for visceral leishmaniasis in HIV infection","volume":"92","author":"Lafeuillade","year":"1992"},{"key":"R12","series-title":"Trans R Soc Trop Med Hyg","first-page":"221","article-title":"Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate","volume":"84","author":"Chunge","year":"1990"},{"key":"R13","series-title":"Trans R Soc Trop Med Hyg","first-page":"615","article-title":"Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India","volume":"86","author":"Thakur","year":"1992"},{"key":"R14","series-title":"Trans R Soc Trop Med Hyg","first-page":"219","article-title":"Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial","volume":"89","author":"Thakur","year":"1995"},{"key":"R15","series-title":"Trans R Soc Trop Med Hyg","first-page":"429","article-title":"A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis","volume":"94","author":"Thakur","year":"2000"},{"key":"R16","series-title":"J Infect Dis","first-page":"715","article-title":"Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone","volume":"168","author":"Seaman","year":"1993"},{"key":"R17","series-title":"Medicine (Baltimore)","first-page":"54","article-title":"Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study","volume":"80","author":"Pintado","year":"2001"},{"key":"R18","series-title":"Drugs","first-page":"1009","article-title":"Practical guide for the treatment of leishmaniasis","volume":"56","author":"Davidson","year":"1998"},{"key":"R19","series-title":"Rev Med Interne","first-page":"234","article-title":"Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole","volume":"17","author":"B\u00e9chade","year":"1996"},{"key":"R20","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"365","article-title":"Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients","volume":"17","author":"Angarano","year":"1998"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/83\/1\/article-p10.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/83\/1\/article-p10.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/83\/1\/article-p10.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:57:55Z","timestamp":1725292675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/83\/1\/article-p10.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":20,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.2010.09-0594","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}